{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:09:37Z","timestamp":1787317777290,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that is effective in treating gastrointestinal (GI) cancers. However, the significant variability in its reported efficacy and safety profiles is likely due to differences in trial designs, patient populations, and clinical settings. This systematic review and meta-analysis aimed to consolidate current evidence on the efficacy and safety of T-DXd in human epidermal growth factor receptor 2 (HER2)-positive GI malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systemic Reviews and Meta-Analysis guidelines (PRISMA), utilizing the Medline, Embase, Cochrane Central, and ClinicalTrials.gov databases. Out of 5,594 articles reviewed, 10 studies were ultimately included after both primary and secondary screenings, providing data on the outcomes and safety of T-DXd in HER2-positive GI malignancies. The National Institute of Health quality assessment tool was employed to evaluate the quality of the studies. Pooled analyses were performed using the \u2018meta\u2019 package (Schwarzer et\u00a0al., R programming language), and proportions with 95% confidence intervals (CIs) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 653 patients treated with T-DXd for HER2-positive GI malignancies in 10 studies. The median age of the patients was 64.5 years (27\u201385) and 53% were male. The median follow-up duration was 5.9 months (0.5\u201330.5). The median overall survival and progression-free survival were 11.15 (1.4\u201320.8) and 5.6 months (2.6\u20138.7), respectively. The pooled objective response rate (ORR) was 36.9% (95% CI:31.5%\u201342.5%, I\u00b2 = 41%, n = 589), with partial response and complete response rates of 35.2% (95% CI:31.1%\u201339.5%, I\u00b2 = 0%, n = 516) and 1.3% (95% CI: 0.0%\u20134.7%, I\u00b2 = 73%, n = 516), respectively. The median duration of response (DoR) was 7 months (0.7\u201322.3). Reported adverse events included anemia, febrile neutropenia, thrombocytopenia, diarrhea, nausea, interstitial lung disease\/pneumonitis, heart failure, and hepatitis. For the 5.4 mg\/kg dose, grade 3\/4 adverse events were reported in 67 patients. For the 6.4 mg\/kg dose, 146 grade 3\/4 adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis supports the efficacy of T-DXd in patients with HER2-positive GI malignancies with a moderate ORR, even in patients who have experienced disease progression after multiple lines of therapy. Overall, T-DXd is well-tolerated, with limited severe adverse events. These findings validate existing research and underscore the need for further clinical trials, particularly in earlier lines of treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgstr.2025.1559934","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:26:04Z","timestamp":1745904364000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis"],"prefix":"10.3389","volume":"4","author":[{"given":"Ali","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezza","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Awais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayan","family":"Mainkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Lynn","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Deotare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azka","family":"Tasleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijan","family":"Valasapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munizay","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdi","family":"Battah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahvish","family":"Muzaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_351354","article-title":"HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target","volume":"42","author":"Djaballah","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080990","article-title":"Challenges and future of HER2-positive gastric cancer therapy","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_302_22","article-title":"Fam-trastuzumab deruxtecan-nxki (Enhertu\u00ae): A narrative drug review","volume":"5","author":"Varghese","year":"2022","journal-title":"Cancer Research Statistics Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.3390\/cancers14205115","article-title":"Resistance to trastuzumab","volume":"14","author":"Vivekanandhan","year":"2022","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2020.1755909","article-title":"Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice","volume":"50","author":"Okamoto","year":"2020","journal-title":"Xenobiotica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v145.12","article-title":"[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22648","DOI":"10.1038\/s41598-023-49646-5","article-title":"Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer","volume":"13","author":"Park","year":"2023","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v141.8","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12135","article-title":"Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study","volume":"41","author":"Hong","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.307","article-title":"172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced\/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-ar","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","volume":"40","author":"Ohba","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/jcm11082247","article-title":"Real-world data of trastuzumab deruxtecan for advanced gastric cancer: A multi-institutional retrospective study","volume":"11","author":"Matsumoto","year":"2022","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10147-023-02422-x","article-title":"Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study","volume":"29","author":"Shitara","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.08.019","article-title":"HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships","volume":"43","author":"Grivas","year":"2007","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18007","article-title":"Prognostic significance of HER3 in patients with Malignant solid tumors","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","article-title":"Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad036","article-title":"The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis","volume":"53","author":"Kou","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"B30","article-title":"Epidemiology of colorectal cancer","volume":"7","author":"Marley","year":"2016","journal-title":"Int J Mol Epidemiol Genet"},{"key":"B31","volume-title":"Cancer Facts & Figures\u00a02024","year":"2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5114\/pg.2018.80001","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-019-03430-y","article-title":"ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials","volume":"34","author":"Abdel-Rahman","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2020.1749290","article-title":"Modified glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer","volume":"73","author":"Demirelli","year":"2021","journal-title":"Nutr Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"v98","DOI":"10.1093\/annonc\/mdy150.017","article-title":"Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study","volume":"29","author":"Janssens","year":"2018","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"12306","DOI":"10.1038\/s41598-024-63143-3","article-title":"Prognostic factors and survival disparities in right-sided versus left-sided colon cancer","volume":"14","author":"Asghari-Jafarabadi","year":"2024","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J Gastrointest Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: A systematic review and meta-analysis","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1559934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:26:06Z","timestamp":1745904366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1559934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":39,"alternative-id":["10.3389\/fgstr.2025.1559934"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2025.1559934","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"1559934"}}